Physician profile
Roger S Hoffman
NPI 1194700070
$2,822.13
in general payments reported to CMS, 2019-2025
20 companies · $395 in 2025
The $395 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $319 · 2021: $349 · 2022: $197 · 2023: $353 · 2024: $392 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $723.60 | 2022-2025 | |
| Alcon Vision LLC | $394.91 | 2019-2025 | Argos, Rocklatan, Clareon Panoptix Pro |
| Allergan, INC. | $265.22 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $257.35 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $243.03 | 2019-2023 | Eylea Hd |
| Kala Pharmaceuticals, INC. | $164.70 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $141.83 | 2019-2021 | |
| Horizon Therapeutics Plc | $124.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $117.62 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $82.41 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $62.59 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $49.62 | 2024-2025 | Triesence, Iheezo |
| Bausch & Lomb Americas INC. | $42.26 | 2024-2025 | Ic-8 Apthera Iol, Envista Mx60 Iol |
| Genmab U.S., INC. | $40.56 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $26.57 | 2024 | Rayone Spheric, Rayone Aspheric, Omidria |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $24.31 | 2020 | |
| Glaukos Corporation | $17.83 | 2019 | |
| Sun Pharmaceutical Industries INC. | $16.99 | 2020 | |
| Shire North American Group INC | $13.80 | 2019 | |
| Ocular Therapeutix, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.